Recent Advances in the Research and Development of RAF Kinase Inhibitors

Author(s): Roger A. Smith, Jacques Dumas, Lila Adnane, Scott M. Wilhelm

Journal Name: Current Topics in Medicinal Chemistry

Volume 6 , Issue 11 , 2006

Become EABM
Become Reviewer
Call for Editor


The RAS-RAF-MEK-ERK signaling pathway (ERK pathway) plays a key role in tumorigenesis and cancer progression. Mutations of RAS or B-RAF lead to a constitutive activation of the ERK pathway, which ultimately results in increased cell division, and cell survival. This review article focuses on the recent literature related to ERK pathway inhibitors, with a particular emphasis on RAF kinase inhibitors. Preclinical and clinical data for the RAF kinase inhibitor sorafenib (BAY 43-9006 tosylate), that was recently approved in the US for the treatment of advanced renal cell carcinoma, are also outlined.

Keywords: Sorafenib, BAY 43-9006, RAF-1, C-RAF, B-RAF, kinase inhibitor, MAP kinase

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [1071 - 1089]
Pages: 19
DOI: 10.2174/156802606777812077
Price: $65

Article Metrics

PDF: 9